Status:

UNKNOWN

Xience Versus Synergy in Left Main PCI

Lead Sponsor:

NHS National Waiting Times Centre Board

Collaborating Sponsors:

Boston Scientific Corporation

Venn Life Sciences

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A prospective, randomized, multicenter study in patients with an indication for coronary artery revascularisation who have been accepted for percutaneous coronary intervention (PCI) of the left main c...

Detailed Description

PCI of the left main coronary artery is a complex procedure with increased risk of both short and long-term major cardiac adverse events. With the use of coronary artery stents the outcome has signifi...

Eligibility Criteria

Inclusion

  • Patients with an indication for coronary artery revascularisation by ESC guidelines and accepted for PCI of the left main coronary artery will be included in the study.
  • Main inclusion criteria:
  • Patient has an indication for coronary artery revascularisation of the left main artery in accordance with the ESC guidelines
  • Patient has been discussed with the cardiac surgeon prior to PCI procedure
  • Patient is accepted for PCI
  • Patient is at least 18 years of age.
  • The patient understands and accepts the meaning and the aims of the study and is willing to provide written informed consent
  • The patient is willing to comply with specified follow-up evaluation and can be contacted by telephone.

Exclusion

  • Not able to receive anti-platelet treatment due to contraindications
  • Known allergy to acetylsalicylic acid, clopidogrel, prasugrel or ticagrelor
  • Cardiogenic shock
  • STEMI within the last 5 days
  • Planned surgery within 12 months after stent introduction
  • History of bleeding diathesis or active major bleedings
  • Major surgery within previous 15 days
  • Current participation in another trial which has not yet reached its primary endpoint
  • Life expectancy \< 12 months
  • Hypersensitivity or contraindication to everolimus or structurally-related compounds, cobalt, chromium, nickel, tungsten, acrylic, platinum and fluoropolymers
  • Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding

Key Trial Info

Start Date :

December 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2020

Estimated Enrollment :

818 Patients enrolled

Trial Details

Trial ID

NCT02303717

Start Date

December 1 2014

End Date

December 1 2020

Last Update

December 1 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.